AU734312B2 - Administration of polypeptide growth factors following central nervous system ischemia or trauma - Google Patents

Administration of polypeptide growth factors following central nervous system ischemia or trauma Download PDF

Info

Publication number
AU734312B2
AU734312B2 AU25529/97A AU2552997A AU734312B2 AU 734312 B2 AU734312 B2 AU 734312B2 AU 25529/97 A AU25529/97 A AU 25529/97A AU 2552997 A AU2552997 A AU 2552997A AU 734312 B2 AU734312 B2 AU 734312B2
Authority
AU
Australia
Prior art keywords
administration
growth factor
injury
animals
bfgf
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU25529/97A
Other languages
English (en)
Other versions
AU2552997A (en
Inventor
Seth P Finklestein
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
General Hospital Corp
Original Assignee
General Hospital Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24485972&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU734312(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by General Hospital Corp filed Critical General Hospital Corp
Publication of AU2552997A publication Critical patent/AU2552997A/en
Application granted granted Critical
Publication of AU734312B2 publication Critical patent/AU734312B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1875—Bone morphogenic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Control Of Electric Motors In General (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Control Of Motors That Do Not Use Commutators (AREA)
  • Protection Of Generators And Motors (AREA)
AU25529/97A 1996-03-22 1997-03-21 Administration of polypeptide growth factors following central nervous system ischemia or trauma Ceased AU734312B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US62044496A 1996-03-22 1996-03-22
US08/620444 1996-03-22
PCT/US1997/005071 WO1997034618A1 (en) 1996-03-22 1997-03-21 Administration of polypeptide growth factors following central nervous system ischemia or trauma

Publications (2)

Publication Number Publication Date
AU2552997A AU2552997A (en) 1997-10-10
AU734312B2 true AU734312B2 (en) 2001-06-07

Family

ID=24485972

Family Applications (2)

Application Number Title Priority Date Filing Date
AU25529/97A Ceased AU734312B2 (en) 1996-03-22 1997-03-21 Administration of polypeptide growth factors following central nervous system ischemia or trauma
AU25823/97A Ceased AU725341B2 (en) 1996-03-22 1997-03-21 Methods for enhancing functional recovery following central nervous system ischemia or trauma

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU25823/97A Ceased AU725341B2 (en) 1996-03-22 1997-03-21 Methods for enhancing functional recovery following central nervous system ischemia or trauma

Country Status (11)

Country Link
US (4) US6407060B1 (enExample)
EP (3) EP1364655B1 (enExample)
JP (2) JP2000507939A (enExample)
KR (1) KR20000064752A (enExample)
CN (1) CN1181885C (enExample)
AT (2) ATE493141T1 (enExample)
AU (2) AU734312B2 (enExample)
CA (2) CA2249368A1 (enExample)
DE (2) DE69740089D1 (enExample)
ES (1) ES2201287T5 (enExample)
WO (2) WO1997034626A1 (enExample)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6150328A (en) 1986-07-01 2000-11-21 Genetics Institute, Inc. BMP products
US6077823A (en) * 1991-03-11 2000-06-20 Creative Biomolecules, Inc. Method for reducing tissue damage associated with ischemia-reperfusion or hypoxia injury
ES2213745T3 (es) 1993-05-12 2004-09-01 Genetics Institute, Llc Composiciones de bmp-11.
US6291206B1 (en) 1993-09-17 2001-09-18 Genetics Institute, Inc. BMP receptor proteins
ES2255059T3 (es) 1993-12-07 2006-06-16 Genetics Institute, Llc Bmp-12, bmp-13 y composiciones suyas inductoras de tendon.
US6498142B1 (en) 1996-05-06 2002-12-24 Curis, Inc. Morphogen treatment for chronic renal failure
AU5244998A (en) * 1996-11-15 1998-06-03 Creative Biomolecules, Inc. Morphogen-induced regeneration of sense perceptory tissues
ATE278414T1 (de) 1997-05-05 2004-10-15 Curis Inc Therapien zur behandlung von akutem nierenversagen
AU742663B2 (en) * 1997-05-30 2002-01-10 Stryker Corporation Methods for evaluating tissue morphogenesis and activity
CA2314423A1 (en) * 1997-12-04 1999-06-10 Creative Biomolecules, Inc. Maintenance of smooth muscle integrity by morphogenic proteins
US20030170213A1 (en) * 1998-01-23 2003-09-11 Marc F. Charette Methods and compositions for enhancing cognitive function using morphogenic proteins
US7147839B2 (en) 1998-05-29 2006-12-12 Curis, Inc. Methods for evaluating tissue morphogenesis and activity
DE19837230A1 (de) * 1998-08-17 2000-03-09 Jean Krutmann Neurotrophin-4 zur Behandlung von Tumoren neuroektodermalen Ursprungs
US6727224B1 (en) 1999-02-01 2004-04-27 Genetics Institute, Llc. Methods and compositions for healing and repair of articular cartilage
MXPA02001719A (es) * 1999-08-18 2003-09-25 Childrens Medical Center METODOS, COMPOSICIONES Y EQUIPOS PARA PROMOVER LA RECUPERACION DEL DAnO AL SISTEMA NERVIOSO CENTRAL.
US6749850B1 (en) 1999-08-18 2004-06-15 The General Hospital Corporation Methods, compositions and kits for promoting recovery from damage to the central nervous system
ATE271886T1 (de) 1999-10-15 2004-08-15 Inst Genetics Llc Hyaluronsäure enthaltende zusammensetzungen zur abgabe osteogener proteine
US7060676B2 (en) * 1999-12-20 2006-06-13 Trustees Of Tufts College T. cruzi-derived neurotrophic agents and methods of use therefor
US7541184B2 (en) 2000-02-24 2009-06-02 Invitrogen Corporation Activation and expansion of cells
US7572631B2 (en) 2000-02-24 2009-08-11 Invitrogen Corporation Activation and expansion of T cells
JP2003534385A (ja) 2000-06-01 2003-11-18 チルドレンズ メディカル センター コーポレーション 被験者の神経に有益な効果をもたらす方法および組成物
US6855690B2 (en) 2000-06-01 2005-02-15 Children's Medical Center Corporation Methods and compositions for treating ocular disorders
TW200526779A (en) 2001-02-08 2005-08-16 Wyeth Corp Modified and stabilized GDF propeptides and uses thereof
US7700819B2 (en) 2001-02-16 2010-04-20 Kci Licensing, Inc. Biocompatible wound dressing
US7763769B2 (en) 2001-02-16 2010-07-27 Kci Licensing, Inc. Biocompatible wound dressing
US20030022210A1 (en) * 2001-06-01 2003-01-30 Mark Bonyhadi T cell induced tissue repair and regeneration
DE60226321T2 (de) 2001-06-01 2009-07-09 Wyeth Zusammensetzungen für die systemische verabreichung von sequenzen, die für knochenmorphogenese-proteinen kodieren
TWI267378B (en) 2001-06-08 2006-12-01 Wyeth Corp Calcium phosphate delivery vehicles for osteoinductive proteins
US20060259014A1 (en) 2002-05-22 2006-11-16 Surgimark, Inc. Aspirator sleeve and suction handle
WO2004047871A2 (en) 2002-11-26 2004-06-10 Nobex Corporation Modified naturetic compounds, conjugates, and uses thereof
US20040229292A1 (en) * 2002-11-26 2004-11-18 Sebastiano Cavallaro Use of FGF-18 in the diagnosis and treatment of memory disorders
EP1623017B1 (en) 2003-05-08 2010-09-15 Life Technologies Corporation Generation and isolation of antigen-specific t cells
WO2006009836A2 (en) 2004-06-17 2006-01-26 Thrasos Therapeutics, Inc. Tdf-related compounds and analogs thereof
EP2453024B1 (en) 2004-06-21 2017-12-06 The Board of Trustees of The Leland Stanford Junior University Genes and pathways differentially expressed in bipolar disorder and/or major depressive disorder
WO2006012365A2 (en) * 2004-07-20 2006-02-02 University Of Maryland Protease inhibitor
US20090082263A1 (en) * 2004-07-29 2009-03-26 Anges, Mg, Inc. Drug and method for improving brain function
US8697139B2 (en) 2004-09-21 2014-04-15 Frank M. Phillips Method of intervertebral disc treatment using articular chondrocyte cells
GB0425625D0 (en) * 2004-11-22 2004-12-22 Royal College Of Surgeons Ie Treatment of disease
HUE026634T2 (en) 2005-09-20 2016-07-28 Thrasos Innovation Inc TDF-related compounds and analogues thereof
DK2564864T3 (en) 2005-11-12 2015-04-07 Trustees Of The Leland Board Of FGF-2 related methods for the diagnosis and treatment of depression
AU2007234612B2 (en) * 2006-12-14 2013-06-27 Johnson & Johnson Regenerative Therapeutics, Llc Protein stabilization formulations
HRP20120698T1 (hr) * 2007-01-25 2013-09-30 Biopharm Gesellschaft Zur Biotechnologischen Entwicklung Von Pharmaka Mbh Uporaba dgf-5 za poboljšanje ili održavanje izgleda kože
US7678764B2 (en) 2007-06-29 2010-03-16 Johnson & Johnson Regenerative Therapeutics, Llc Protein formulations for use at elevated temperatures
CA2695697A1 (en) 2007-08-07 2009-02-12 Advanced Technologies And Regenerative Medicine, Llc Protein formulations comprising gdf-5 in aqueous acidic solution
BRPI0911048A2 (pt) * 2008-04-14 2015-12-29 Atrm Llc formulações líquidas tamponadas de gdf-5
SG173634A1 (en) * 2009-02-12 2011-09-29 Stryker Corp COMPOSITIONS AND METHODS FOR MINIMALLY-INVASIVE SYSTEMIC DELIVERY OF PROTEINS INCLUDING TGF-ß SUPERFAMILY MEMBERS
EP2396025A2 (en) * 2009-02-12 2011-12-21 Stryker Corporation Peripheral administration of proteins including tgf-beta superfamily members for systemic treatment of disorders and disease
US8828937B2 (en) 2009-03-12 2014-09-09 Haase Investments Ug Bone morphogenetic protein 2 (BMP2) variants with reduced BMP antagonist sensitivity
WO2010144696A1 (en) 2009-06-11 2010-12-16 Burnham Institute For Medical Research Directed differentiation of stem cells
EP2352750B1 (en) 2009-09-17 2012-06-13 Stryker Corporation Buffers for controlling the ph of bone morphogenetic proteins
EP2516456A1 (en) 2009-12-22 2012-10-31 Stryker Corporation Bmp-7 variants with reduced immunogenicity
CN101822815A (zh) * 2010-04-29 2010-09-08 广东八加一医药有限公司 系列多肽小分子在制备防治缺血性脑血管疾病药物中的应用
US9688735B2 (en) 2010-08-20 2017-06-27 Wyeth Llc Designer osteogenic proteins
WO2012023113A2 (en) 2010-08-20 2012-02-23 Wyeth Llc Designer osteogenic proteins
CA2829006A1 (en) 2011-03-04 2012-09-13 The Regents Of The University Of California Locally released growth factors to mediate motor recovery after stroke
KR101274930B1 (ko) * 2011-06-03 2013-06-17 전남대학교산학협력단 골 형성 또는 혈관신생 촉진용 펩타이드 ｂｆｐ 4 및 이의 용도
BR112014001268A2 (pt) * 2011-07-19 2017-02-21 Thrasos Innovation Inc peptídeos antifibróticos e seu uso em métodos para tratamento de doenças e distúrbios caracterizados por fibrose
EP2784083A1 (en) 2013-03-28 2014-10-01 Charité - Universitätsmedizin Berlin Bone Morphogenetic Protein (BMP) variants with highly reduced antagonist sensitivity and enhanced specific biological activity
EP2981822B1 (en) 2013-05-06 2020-09-02 Scholar Rock, Inc. Compositions and methods for growth factor modulation
WO2014201143A1 (en) * 2013-06-11 2014-12-18 President And Fellows Of Harvard College Methods and compositions for increasing neurogenesis and angiogenesis
EP3543339A1 (en) 2015-02-13 2019-09-25 Factor Bioscience Inc. Nucleic acid products and methods of administration thereof
CN116115629A (zh) 2016-08-17 2023-05-16 菲克特生物科学股份有限公司 核酸产品及其施用方法
BR112021000018A2 (pt) * 2018-07-03 2021-07-06 Venturis Therapeutics Inc composições e métodos para tratamento de acidente vascular cerebral
CN115190886A (zh) * 2020-02-20 2022-10-14 马斯特里赫特大学 循环bmp10（骨形态发生蛋白10）的检测方法
WO2021236824A1 (en) * 2020-05-19 2021-11-25 Elevian, Inc. Methods and compositions for treating stroke
WO2024259004A1 (en) * 2023-06-13 2024-12-19 Bedford Research Foundation Systems and methods of cell transport at ambient temperature

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4994559A (en) * 1985-12-17 1991-02-19 Synergen, Inc. Human basic fibroblast growth factor
EP0501445A1 (en) * 1991-02-27 1992-09-02 Yeda Research And Development Co. Ltd. Pharmaceutical composition comprising interleukin-2
WO1993009802A2 (en) * 1991-11-22 1993-05-27 Genentech, Inc. Tgf-beta to improve neural outcome

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4440860A (en) 1980-01-18 1984-04-03 The Children's Medical Center Corporation Stimulating cell growth
US4378347A (en) * 1980-06-30 1983-03-29 Franco Wayne P Composition for treating the heart for myocardial infarction
US4296100A (en) 1980-06-30 1981-10-20 Franco Wayne P Method of treating the heart for myocardial infarction
DE3110560A1 (de) 1981-03-18 1982-10-14 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V., 3400 Göttingen "angiotropine der leukozyten und des entzuendungsgewebes: eine neue klasse natuerlicher chemotropischer mitogene fuer das richtungswachstum von blutgefaessen und zur neovaskularisierung von geweben"
EP0105014B1 (en) 1982-09-24 1992-05-20 THE UNITED STATES OF AMERICA as represented by the Secretary United States Department of Commerce Repair of tissue in animals
US4806523A (en) 1985-08-06 1989-02-21 Collagen Corporation Method of treating inflammation
US4971952A (en) 1986-03-06 1990-11-20 Collagen Corporation Method of treating inflammation with cartilage inducing factor
IL83003A (en) 1986-07-01 1995-07-31 Genetics Inst Osteoinductive factors
US4801575A (en) 1986-07-30 1989-01-31 The Regents Of The University Of California Chimeric peptides for neuropeptide delivery through the blood-brain barrier
CA1322714C (en) 1986-11-14 1993-10-05 Harry N. Antoniades Wound healing and bone regeneration
EP0269408A3 (en) 1986-11-26 1989-08-30 Genentech, Inc. Tgf-beta in the treatment of inflammatory disorders
US4797277A (en) 1987-09-22 1989-01-10 Pharmacia Ab Method for reperfusion therapy
US5011691A (en) 1988-08-15 1991-04-30 Stryker Corporation Osteogenic devices
US5108753A (en) 1988-04-08 1992-04-28 Creative Biomolecules Osteogenic devices
JPH0262829A (ja) 1988-05-18 1990-03-02 Nippon Kayaku Co Ltd 虚血に基づく傷害の予防及び治療剤
US4983581A (en) 1988-05-20 1991-01-08 Institute Of Molecular Biology, Inc. Wound healing composition of IGF-I and TGF-β
HU201095B (en) 1988-06-14 1990-09-28 Richter Gedeon Vegyeszet New peptides inhibiting the activity of the immune system and pharmaceutical compositions comprising same, as well as process for producing these peptides and compositions
FI910081A0 (fi) 1988-07-08 1991-01-07 Univ London Analys av cellmodifierande substanser.
AU4056089A (en) 1988-07-20 1990-02-19 Amgen, Inc. Method of treating inflammatory disorders by reducing phagocyte activation
US5057494A (en) 1988-08-03 1991-10-15 Ethicon, Inc. Method for preventing tissue damage after an ischemic episode
US5106626A (en) 1988-10-11 1992-04-21 International Genetic Engineering, Inc. Osteogenic factors
US5135915A (en) 1988-10-14 1992-08-04 Genentech, Inc. Method for the treatment of grafts prior to transplantation using TGF-.beta.
US5011914A (en) 1989-01-05 1991-04-30 Collins Franklin D Purified ciliary neurotrophic factor
US5002965A (en) 1989-05-09 1991-03-26 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) Use of ginkgolides to prevent reperfusion injury in organ transplantation
US5118791A (en) 1989-05-25 1992-06-02 Genentech, Inc. Biologically active polypeptides based on transforming growth factor-β
US5158934A (en) 1989-09-01 1992-10-27 Genentech, Inc. Method of inducing bone growth using TGF-β
JP2845346B2 (ja) 1989-10-17 1999-01-13 ストライカー・コーポレーション 骨形成具
US5108989A (en) 1990-04-04 1992-04-28 Genentech, Inc. Method of predisposing mammals to accelerated tissue repair
DE69131580T2 (de) 1990-06-15 2000-01-13 Carnegie Institution Of Washington, Washington GDF-1 und UOG1 Proteine
ATE253589T1 (de) 1990-09-26 2003-11-15 Inst Genetics Llc Bmp-5-derivate
DK0643767T3 (da) 1990-10-18 1999-04-26 Stryker Corp Osteogene peptider
AU660635B2 (en) 1990-11-16 1995-07-06 Celtrix Pharmaceuticals, Inc. A beta-type transforming growth factor
EP1142581A3 (en) 1990-11-27 2002-09-11 American National Red Cross Tissue sealant and growth factor containing compositions that promote accelerated wound healing
WO1992009697A1 (en) 1990-11-30 1992-06-11 Celtrix Laboratories, Inc. USE OF A BONE MORPHOGENETIC PROTEIN IN SYNERGISTIC COMBINATION WITH TGF-β FOR BONE REPAIR
DK0575555T3 (da) 1991-03-11 2001-11-05 Curis Inc Proteininduceret morfogenese
US5118667A (en) 1991-05-03 1992-06-02 Celtrix Pharmaceuticals, Inc. Bone growth factors and inhibitors of bone resorption for promoting bone formation
CA2102808A1 (en) 1991-05-10 1992-11-11 Hanne Bentz Targeted delivery of bone growth factors
CA2086327A1 (en) 1991-05-10 1992-11-11 Lawrence S. Mathews Cloning and recombinant production of receptor(s) of the activin/tgf- .beta. superfamily
KR0145278B1 (ko) 1991-06-21 1998-07-15 브루스 엠. 에이센 골형성원 단백질 약제
WO1993000432A1 (en) 1991-06-25 1993-01-07 Genetics Institute, Inc. Bmp-9 compositions
DE69231567T2 (de) 1991-08-30 2001-06-28 Creative Biomolecules, Inc. Screeningverfahren von morphogenischen Proteinen
CA2116562C (en) * 1991-08-30 1999-04-13 Thangavel Kuberasampath Morphogen-induced modulation of inflammatory response
ATE308336T1 (de) 1991-08-30 2005-11-15 Curis Inc Osteogenische proteine in der behandlung von metabolischen knochenkrankheiten
WO1993009229A1 (en) 1991-11-04 1993-05-13 Genetics Institute, Inc. Recombinant bone morphogenetic protein heterodimers, compositions and methods of use
WO1993008828A1 (en) * 1991-11-08 1993-05-13 Syntex-Synergen Neuroscience Joint Venture Methods for the treatment of neuronal damage associated with ischemia, hypoxia or neurodegeneration
DE19525416A1 (de) † 1995-07-12 1997-01-16 Bioph Biotech Entw Pharm Gmbh Verwendung von MP52 zur Behandlung und Prävention von Erkrankungen des Nervensystems
WO1994003200A1 (en) 1992-07-31 1994-02-17 Creative Biomolecules, Inc. Morphogen-induced nerve regeneration and repair
ES2061380B1 (es) * 1992-11-23 1995-07-01 Boehringer Ingelheim Espana Empleo del factor de crecimiento fibroblastico y sus derivados como neuroprotectores y neuromoduladores.
DE69434739T2 (de) 1993-08-26 2007-05-10 Genetics Institute, LLC, Cambridge Menschliche Knochen-morphogenetische Proteine zur Verwendung bei neuronaler Rehgeneration
AU7605394A (en) 1993-09-03 1995-03-22 Regents Of The University Of California, The Neural tissue affecting factor and compositions
JPH09503673A (ja) 1993-10-14 1997-04-15 プレジデント・アンド・フエローズ・オブ・ハーバード・カレツジ ニューロン細胞の誘導および維持法
AU6787594A (en) 1994-03-10 1995-09-25 Human Genome Sciences, Inc. Bone morphogenic protein-10
AU5244998A (en) * 1996-11-15 1998-06-03 Creative Biomolecules, Inc. Morphogen-induced regeneration of sense perceptory tissues

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4994559A (en) * 1985-12-17 1991-02-19 Synergen, Inc. Human basic fibroblast growth factor
EP0501445A1 (en) * 1991-02-27 1992-09-02 Yeda Research And Development Co. Ltd. Pharmaceutical composition comprising interleukin-2
WO1993009802A2 (en) * 1991-11-22 1993-05-27 Genentech, Inc. Tgf-beta to improve neural outcome

Also Published As

Publication number Publication date
AU2582397A (en) 1997-10-10
AU725341B2 (en) 2000-10-12
AU2552997A (en) 1997-10-10
US6214796B1 (en) 2001-04-10
EP1364655B1 (en) 2010-12-29
EP0894004A1 (en) 1999-02-03
CA2249596A1 (en) 1997-09-25
CA2249596C (en) 2011-11-08
DE69740089D1 (de) 2011-02-10
ATE493141T1 (de) 2011-01-15
DE69723429T3 (de) 2007-09-20
DE69723429T2 (de) 2004-04-22
WO1997034626A1 (en) 1997-09-25
EP0894004B1 (en) 2003-07-09
EP0904093A1 (en) 1999-03-31
US6407060B1 (en) 2002-06-18
WO1997034618A1 (en) 1997-09-25
CN1219133A (zh) 1999-06-09
CA2249368A1 (en) 1997-09-25
EP1364655A1 (en) 2003-11-26
DE69723429D1 (de) 2003-08-14
CN1181885C (zh) 2004-12-29
EP0904093A4 (en) 2004-11-17
US20010039261A1 (en) 2001-11-08
EP0894004B2 (en) 2007-02-21
KR20000064752A (ko) 2000-11-06
US20030022830A1 (en) 2003-01-30
JP2000506894A (ja) 2000-06-06
ES2201287T3 (es) 2004-03-16
JP4847634B2 (ja) 2011-12-28
JP2000507939A (ja) 2000-06-27
ES2201287T5 (es) 2007-10-16
ATE244574T1 (de) 2003-07-15

Similar Documents

Publication Publication Date Title
AU734312B2 (en) Administration of polypeptide growth factors following central nervous system ischemia or trauma
US5733871A (en) Methods for the treatment of neuronal damage associated with ischemia, hypoxia or neurodegeneration
Tuszynski Intraparenchymal NGF infusions rescue degenerating cholinergic neurons
US7304029B1 (en) Neuroprotective effect of growth hormone
EP0862452B1 (en) Stabilizing formulation for ngf
US20040209812A1 (en) Use of erythropoietin in stroke recovery
Bäckman et al. Effects of transferrin receptor antibody-NGF conjugate on young and aged septal transplants in oculo
US6090781A (en) Stabilizing formulation for NGF
JP2001504123A (ja) Ｃｎｓ障害に対して保護するための成長因子を用いた予備治療
EP1100523A1 (en) Treatment of central nervous system ischemia or trauma with epidermal growth factor-like polypeptides
Gao et al. The therapeutic potentials of neurotrophic factors for diseases of the nervous system
Zuch et al. Beneficial effects of intraventricularly administered BMP-7 following a striatal 6-hydroxydopamine lesion
CA2304720A1 (en) Apolipoprotein e/growth factor complexes and methods of use
EP1832296B1 (en) Compositions based on Midkine for the treatment of chronic stage injury of the heart after ischemia/reperfusion
US6964947B1 (en) Stabilizing formulation for NGF
CA2619721A1 (en) Use of nerve growth factor in eye-drops for therapy of pathologies of the central nervous system, such as alzheimer's and parkinson's disease
HK1015261B (en) Stabilizing formulation for ngf
WO2000033864A1 (fr) Remedes contre les defaillances tactiles

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)